NPI-001 Enters Confirmatory Phase 3 With Small N and No Matched Precedent

Nacuity Doses First Patient in Phase 3 SLO-RP Preserve Trial

Nacuity Pharmaceuticals has announced the dosing of the first patient in its global, confirmatory Phase 3 SLO-RP Preserve clinical trial for NPI-001, an N-acetylcysteine amide tablet, targeting retinitis pigmentosa (RP) associated with Usher Syndrome. This rare, progressive inherited retinal disease currently lacks approved therapies to slow photoreceptor degeneration. The 24-month, randomized, double-masked study aims to enroll up to 80 adult participants who will self-administer NPI-001 or a placebo twice daily orally. The trial builds on positive results from a previous Phase 2 study, evaluating NPI-001's potential to slow disease progression by reducing photoreceptor loss.

• The SLO-RP Preserve trial is a global, confirmatory Phase 3 study designed to run for 24 months. It is a randomized, double-masked trial enrolling up to 80 adult participants. Patients will self-administer either NPI-001 or a placebo tablet orally twice daily, completing nine in-clinic visits over approximately two years. The study is actively enrolling patients across multiple sites in the United States and Australia.
• NPI-001 is a proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed to address diseases driven by oxidative stress. Preclinical studies indicate that NPI-001 works by boosting glutathione, the body’s most powerful endogenous antioxidant, to prevent damage to retinal cells from aggressive oxygen molecules. The drug has previously received Fast Track, Breakthrough Therapy, and Orphan Drug designations for RP, which includes seven years of U.S. FDA regulatory exclusivity upon approval.
• Retinitis Pigmentosa associated with Usher Syndrome is a rare, progressive inherited retinal disease that leads to irreversible vision loss, with no currently approved therapies to slow photoreceptor degeneration. Nacuity Pharmaceuticals is highly encouraged by positive Phase 2 results and is committed to advancing NPI-001 as a potential disease-modifying therapy. Dosing the first patient marks a significant milestone for the company and the Usher syndrome community, aiming to preserve vision for these patients.

The Urgent Need for New Therapies in RP Associated with Usher Syndrome

Retinitis pigmentosa (RP) in the context of Usher syndrome (USH) presents a particularly complex therapeutic challenge: while cochlear implants and hearing aids have meaningfully addressed the auditory component of the disease, no approved treatment exists to slow or arrest the progressive photoreceptor degeneration that leads to blindness. Current management remains largely supportive, and the gap between hearing and vision care options underscores the urgency for novel retinal therapeutics.

• No disease-modifying therapy for RP exists. There is currently no treatment that stops the evolution of RP or restores vision in USH patients. The therapeutic approach is restricted to slowing the degenerative process through sunlight protection and vitaminotherapy, treating complications such as cataract and macular edema, and helping patients cope with the social and psychological impact of blindness.

• Extreme genetic heterogeneity complicates targeted intervention. USH-associated RP arises from mutations across at least nine confirmed causative genes, with USH2A alone accounting for the greatest proportion of cases — including more than 30% attributable to frameshift mutations on exon 13. Variants in these genes also contribute to isolated forms of hearing loss and RP, indicating intersecting molecular pathways that complicate the design of broadly applicable gene-based therapies.

• Absence of clinically relevant animal models has historically impeded translational research. Until recently, no mammalian model recapitulated the full USH2 phenotype of progressive RP alongside hearing loss. The USH2A mutant rabbit, reported as the first such model, only recently became available to support pathogenesis studies and therapeutic development.

• Light-induced photoreceptor vulnerability adds an environmental dimension to disease progression. USH mouse models — including shaker1 (USH1B) and whirler (USH2D) mice — demonstrate that defective rod transducin translocation renders photoreceptors susceptible to degeneration even under moderate light exposure. This suggests that environmental light management may be a necessary but underutilized adjunct to any future pharmacological strategy.

• Surgical interventions address only focal complications, not underlying degeneration. Procedures such as pars plana vitrectomy for full-thickness macular hole closure can preserve residual central vision in individual USH patients, but do not alter the course of the underlying retinal dystrophy. Similarly, cataract surgery significantly improves best-corrected visual acuity in retinal dystrophy patients, yet posterior capsule opacification (occurring in 66.7% of eyes) and cystoid macular edema (13.3% of eyes) represent elevated complication risks compared to the general cataract population.

• Emerging therapeutic strategies remain investigational. Gene therapy, neuroprotection, retinal prostheses, antisense oligonucleotides, and small-molecule drugs are under investigation, but none has yet reached approved status for USH-associated RP. The Argus II retinal prosthesis has been implanted in individual USH patients — including the first deaf-blind patient in Russia — with reported improvements in independence, though the approach addresses end-stage disease rather than preventing degeneration.

NPI-001's Phase 3 SLO-RP Preserve Trial Design and Goals

Several studies have characterized the functional and structural endpoints used to evaluate retinitis pigmentosa (RP) in the context of Usher syndrome, spanning electrophysiology, imaging, and psychophysical measures. The body of evidence draws on both prospective cohort studies and retrospective case series, with patient populations ranging from single-center case reports to multicenter European cohorts of 268 genetically confirmed individuals.

NPI-001's Position in the Evolving RP Usher Syndrome Landscape

The treatment landscape for RP associated with Usher syndrome has advanced meaningfully, driven primarily by progress in gene therapy. Usher syndrome — a leading cause of deaf-blindness affecting approximately 400,000 patients worldwide — is caused by mutations across 10 identified genes, with three defined clinical subtypes (USH1–3). For years, no biological treatments were available for either the auditory or visual dysfunction associated with the condition. That picture has begun to shift: gene transfer strategies and CRISPR/Cas9-based editing tools have moved from preclinical animal models into early-phase clinical investigation, with trials now targeting the USH2A gene in Usher Syndrome Type 2. Sixteen clinical trials with published results reporting gene therapy for genetic ocular diseases in children have been identified, with Usher Syndrome Type 2 (USH2A) among the diseases under active investigation. Most of these trials remain in Phases 1 or 2, though five studies across the broader inherited retinal disease space have progressed to Phase 3.

Despite this momentum, the translation from animal models to clinical benefit in Usher syndrome has faced persistent challenges. A critical limitation noted in the literature is that very few mouse models of Usher syndrome recapitulate the retinal phenotype observed in human patients, complicating preclinical-to-clinical translation specifically for the visual component of the disease. Promising recovery of hearing and balance functions has been demonstrated via distinct therapeutic strategies in animal models, but clinical translation calls for further improvements. More recently, new preclinical platforms — including induced pluripotent stem cells and organoid models — have been developed for most Usher subtypes to better support therapy development, and an updated pipeline of genetic therapies using these models is now feeding into clinical trials.

The broader RP therapeutic context also informs the Usher syndrome landscape. The FDA approval of voretigene neparvovec for RPE65-associated RP established a regulatory precedent for gene replacement in inherited retinal dystrophies, spurring development across multiple genotypes. Non-viral vectors, nanoparticle delivery systems, and artificial intelligence-guided diagnostics are being explored to address ongoing challenges in delivery efficiency and immune responses — limitations that are particularly relevant for Usher syndrome given the size of some of the implicated genes. Validated outcome measures, such as the MOST mobility test (demonstrating test-retest correlations >0.98 and VR/RL correlations of 0.98), are also being developed to better characterize disease progression and therapeutic benefit in rod-cone dystrophies, supporting more rigorous endpoint selection in future Usher syndrome trials.

Oral Neuroprotection: Reshaping Inherited Retinal Disease Treatment

The initiation of Nacuity Pharmaceuticals' Phase 3 SLO-RP Preserve trial for NPI-001 represents a pivotal moment for individuals living with Usher Syndrome-associated retinitis pigmentosa (RP). This devastating inherited retinal disease currently offers no approved treatments to slow the progressive degeneration of photoreceptor cells, leaving patients facing inevitable vision loss. NPI-001, an N-acetylcysteine amide tablet, aims to fill this critical unmet need by leveraging its established antioxidant, anti-apoptotic, anti-inflammatory, and neuroprotective properties.

Should NPI-001 demonstrate efficacy in slowing photoreceptor degeneration, it would mark a significant shift in the therapeutic landscape. As an oral, systemic therapy, it offers a distinct advantage in terms of patient convenience and accessibility compared to the often-invasive delivery methods of gene therapies, which are currently a major focus in inherited retinal disease research. This could position NPI-001 as a foundational disease-modifying treatment, moving beyond symptomatic management to actively preserving vision. Furthermore, successful validation of N-acetylcysteine amide's neuroprotective mechanism in Usher syndrome could unlock its potential for broader application across other inherited retinal diseases or even other neurodegenerative conditions driven by similar pathological pathways.

However, the path forward is not without its complexities. Usher syndrome is characterized by significant clinical and genetic heterogeneity, with a multitude of causative mutations. This inherent variability could lead to diverse patient responses to a non-gene-specific therapy, posing a challenge to achieving consistent trial outcomes. Additionally, the design of clinical trials for RP must carefully account for regional disease variation and the presence of areas with preserved central retinal function, ensuring that outcome measures accurately capture treatment effects. The competitive landscape is also evolving rapidly, with numerous gene supplementation therapies in development for specific monogenic inherited retinal diseases, including Usher syndrome. These targeted genetic approaches, if successful, could offer a more definitive, potentially curative solution, presenting a formidable challenge to a broad neuroprotective agent. Navigating these factors will be crucial for NPI-001's ultimate success and its ability to carve out a meaningful role in the future of inherited retinal disease treatment.